Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 5Myeloid 3Tumor-Agnostic 1Sarcoma 1Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Psoriasis 1Melanoma 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Etanercept × Dermatologic × Clear all
NCT01053819 2018-02-23

Can We Miss Pigmented Lesions in Psoriasis Patients?

University of Alabama at Birmingham

Phase 4 Completed
6 enrolled 3 charts
Dermatologic

Melanoma, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡